Levels of SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination

@article{Souza2021LevelsOS,
  title={Levels of SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination},
  author={William M. Souza and Mariene R. Amorim and Renata Sesti-Costa and Daniel A. Toledo-Teixeira and Priscilla P. Barbosa and Karina Bispo-Dos-Santos and Camila L. Simeoni and Natalia S. Brunetti and Ingra M. Claro and Adriana Silva Santos Duarte and Thais M. Coletti and Audrey Basso Zangirolami and Carolina Costa-Lima and Lucas I. Buscaratti and Flavia C. S. Sales and Vitor A. Costa and Lucas Augusto Moyses Franco and Darlan da S. Candido and Oliver G. Pybus and Jaqueline G{\'o}es de Jesus and Camila A. M. Silva and Mariana S. Ramundo and Giulia M. Ferreira and Mariana C. Pinho and Leandro Marques de Souza and Esmenia C. Rocha and Pamela dos Santos Andrade and Myuki A. E. Crispim and Grazielle Celeste Maktura and Erika R. Manuli and Magnun Nueldo Nunes Santos and Cecilia da C. Camilo and Rodrigo Nogueira Angerami and Maria Luiza Moretti and Fernando Rosado Spilki and Clarice Weis Arns and Marcelo Addas-Carvalho and Marcelo A. Mori and Alessandro S. Farias and Nuno R. Faria and Ester Cerdeira Sabino and Fabiana Granja},
  journal={Social Science Research Network},
  year={2021}
}
Background: A new SARS-CoV-2 lineage, named P.1 (20J/501Y.V3), has recently been detected in Brazil. Mutations accrued by the P.1 lineage include amino acid changes in the receptor-binding domain of the spike protein that also are reported in variants of concern in the United Kingdom (B.1.1.7) and South Africa (B.1.325). Methods: We isolated two P.1-containing specimens from nasopharyngeal and bronchoalveolar lavage samples of patients of Manaus, Brazil. We measured neutralization of the P.1… 
Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
TLDR
The study demonstrated 1.92 and 1.09 fold reductions in the neutralizing titer against B.1.1-CoV-2 variant in comparison with prototype D614G variant with sera of vaccine recipients and natural infection respectively.
Mild Symptomatic SARS-CoV-2 P.1 (B.1.1.28) Infection in a Fully Vaccinated 83-Year-Old Man
TLDR
An 83-year-old man infected with the SARS-CoV-2 P.1.1 variant after two doses of the BNT162b2 mRNA COVID-19 vaccine is described.
COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies
TLDR
There is convincing evidence of increased susceptibility to SARS-CoV-2 infection among individuals with dysregulated immune response and comorbidities, which provides a comprehensive perspective regarding vulnerability of Sars-CoVs infection in patients with underlying medical comorbridities.
SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies
TLDR
This review summarized the results of the current trend and the latest research studies on the characteristics of the structure and genome of the SARS-CoV- 2, new mutations and variants of Sars- CoV-2, pathogenicity, immune response, virus diagnostic tests, potential treatment, and vaccine candidate.
Novel SARS-CoV-2 variants: the pandemics within the pandemic
TLDR
The emergence of the E484K mutation independently in different parts of the globe may reflect adaptation of SARS-CoV-2 to humans in a background of increasing immunity, and pose challenges to any herd immunity approach of managing the pandemic.
Predominance of SARS-CoV-2 P.1 (Gamma) lineage inducing the recent COVID-19 wave in southern Brazil and the finding of an additional S: D614A mutation
TLDR
Which lineages were circulating in the first quarter of 2021 in southern Brazil to better viral factors involved in the health crisis caused by SARS-CoV-2 in the region is described and two Gamma lineage consensus sequences presented a new S:D614A mutation.
New SARS-CoV-2 lineages could evade CD8+ T-cells response
TLDR
The data provided evidence for the existence of potentially immunogenic and conserved epitopes across new SARS-CoV-2 variants, but also highlights the reduced populational’s coverage for the Brazilian lineage P.2, suggesting its potential to evade from CD8+ T-cell responses.
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
TLDR
The key mutations present in the VOC strains are discussed and insights are provided into how these mutations allow for greater transmissibility and immune evasion than the progenitor strain.
The Emerging Concern and Interest SARS-CoV-2 Variants
TLDR
This analysis summarizes the principal information concerning SARS-CoV-2 variants, such as their infectivity, severity, mutations, and immune susceptibility.
Covid‐19 vaccines and variants of concern: A review
TLDR
The most relevant mutations in the SARS-CoV-2 spike protein are described, VE against VOCs is discussed, and additional effective vaccines are still needed to meet the global demand.
...
1
2
3
...

References

SHOWING 1-10 OF 39 REFERENCES
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera
TLDR
Investigation of SARS-CoV-2-S pseudoviruses bearing either the Wuhan reference strain or the B.1.1-1.7 lineage spike protein finds that the immune sera of 16 participants in a previously reported trial with the mRNA-based COVID-19 vaccine BNT162b2 had equivalent neutralizing titers to both variants.
SARS-CoV-2 variants show resistance to neutralization by many monoclonal and serum-derived polyclonal antibodies
TLDR
As several antibodies binding specific regions of the RBD and NTD show loss-of-neutralization potency in vitro against emerging variants, updated mAb cocktails, targeting of highly conserved regions, enhancement of mAb potency, or adjustments to the spike sequences of vaccines may be needed to prevent loss of protection in vivo.
SARS-CoV-2 B.1.1.7 escape from mRNA vaccine-elicited neutralizing antibodies
TLDR
Assessment of immune responses following vaccination with mRNA-based vaccine BNT162b2 measured neutralising antibody responses following a single immunization using pseudoviruses expressing the wild-type Spike protein or the 8 mutations found in the B.1.1-CoV-2 Spike protein.
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
TLDR
The results suggest that the monoclonal antibodies in clinical use should be tested against newly arising variants, and that mRNA vaccines may need to be updated periodically to avoid potential loss of clinical efficacy.
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
TLDR
It is demonstrated that the immunodominant SARS-CoV-2 spike (S) receptor binding motif (RBM) is a highly variable region of S, and epidemiological, clinical, and molecular characterization of a prevalent, sentinel RBM mutation, N439K is provided.
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
TLDR
It is found that both the magnitude of Ab responses to SARS-CoV-2 spike (S) and nucleoprotein and nAb titers correlate with clinical scores, and the immunodominance of the receptor-binding motif will guide the design of COVID-19 vaccines and therapeutics.
SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo
TLDR
The current dominant structural variant of SARS-CoV-2 appears to have evolved from the ancestral form and enhances transmissibility, and the mutation renders the new virus variant more susceptible to neutralizing antisera without altering the efficacy of vaccine candidates currently under development.
SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma
TLDR
It is shown that pseudovirus expressing 501Y.V2 spike protein completely escapes three classes of therapeutically relevant antibodies and exhibits substantial to complete escape from neutralization, but not binding, by convalescent plasma.
SARS-CoV-2 Uses CD4 to Infect T Helper Lymphocytes
TLDR
It is demonstrated that Sars-CoV-2 spike glycoprotein (S) directly binds to the CD4 molecule, which in turn mediates the entry of SARS- CoV- 2 in T helper cells in a mechanism that also requires ACE2 and TMPRSS2.
Development of an inactivated vaccine candidate for SARS-CoV-2
TLDR
Preclinical results of an early vaccine candidate called PiCoVacc, which protected rhesus macaque monkeys against SARS-CoV-2 infection when analyzed in short-term studies, support the clinical development and testing of Pi coVacc for use in humans.
...
1
2
3
4
...